Last reviewed: May 12, 2026
Last updated: May 12, 2026
Written by:
Jay Hastings
,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision. Browse all Peptides & GLP-1 education
The following is an independent editorial review from PlexusDx. No commercial relationship with Medvi exists, no affiliate links are used, and no compensation is involved.
Retatrutide is one of the most searched names in the metabolic space, which sends shoppers to programs like Medvi expecting to find it. The direct answer: Medvi does not offer retatrutide. This review explains that finding, what retatrutide’s status actually is, and what Medvi provides instead. Fair-balance framing, current as of April 2026.
Start your GLP-1 program with PlexusDx
One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.
Start your intake →
Does Medvi sell retatrutide?
No. As of our July 2026 review, Medvi’s published menu is compounded semaglutide injection, compounded tirzepatide injection, and a once-daily dissolvable GLP-1 tablet, alongside branded Wegovy and Zepbound through a separate membership. We found no retatrutide product in our capture or on Medvi’s live site. See Medvi’s official website for the current menu.
Retatrutide’s investigational status
Retatrutide is an investigational compound that is not FDA-approved. Because it remains under study, this review offers no dosing figures, no injection technique, and no sourcing guidance — and PlexusDx does not sell it. Any site presenting retatrutide as a routine consumer purchase is worth approaching with caution; an investigational molecule is not the same as an approved or compounded therapy with an established regulatory pathway.
What Medvi offers instead
Medvi’s actual lineup sits in the established GLP-1 class. A licensed provider reviews a virtual intake and, where appropriate, issues a prescription filled through a licensed 503A compounding pharmacy for compounded semaglutide or tirzepatide, or a retail pharmacy for branded Wegovy and Zepbound. Ongoing telehealth follow-up supports titration and side-effect management — a model built around approved and compounded compounds, not investigational ones. For a shopper who arrived searching retatrutide, the practical takeaway is that Medvi trades novelty for compounds with a settled regulatory footing and a longer track record.
How Medvi’s GLP-1 program is priced
On the compounded plans, the ongoing rate is $299/month for semaglutide and $399/month for tirzepatide, each with a lower first-month promotional price ($159 and $259 respectively, verified July 2026). Prepaid multi-month plans lower the effective monthly cost — the 3-month semaglutide plan is $475 (about $158/month) and the 12-month tirzepatide plan is $2,859 (about $238/month). Compounded plans carry no membership fee.
Where the evidence stands on approved GLP-1 compounds
The compounds Medvi does offer have a documented record. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a GIP/GLP-1 dual agonist. STEP (semaglutide, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (NEJM 2024) anchor the class. Trial populations and endpoints vary; individual outcomes vary too.
The genetic context that outlasts any single compound
Whichever compound eventually reaches market, the biology underneath stays constant. Variants in FTO, GLP1R (the GLP-1 receptor), MC4R, and TCF7L2 map the metabolic terrain any incretin therapy acts on. They do not predict response to a specific compound, investigational or approved, but they describe your baseline. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with the Precision Peptide Genetic Test, which analyzes 14 pathways, 49 peptides, 150+ genetic insights. That is the test before you invest approach.
Not affiliated: PlexusDx has no relationship with Medvi and no commercial tie to the companies named here.
Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.
Disclaimer: This article is educational. PlexusDx is not affiliated with Medvi and has no commercial relationship with the companies reviewed. Retatrutide is investigational and not FDA-approved; PlexusDx does not sell it. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.
Compare approaches: see the Weight Management Protocols, or take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.
Frequently Asked Questions
Can I get retatrutide through Medvi?
No. As of our July 2026 review, retatrutide does not appear in Medvi’s capture or on its live site. Medvi’s menu is built around compounded semaglutide, compounded tirzepatide, a dissolvable GLP-1 tablet, and branded Wegovy and Zepbound — all established GLP-1 options rather than investigational compounds.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational compound still under study and is not FDA-approved. Because of that status, responsible reviews avoid dosing, technique, or sourcing details, and PlexusDx does not sell it. Treat any consumer offer of retatrutide with caution and consult a qualified provider.
What does Medvi offer instead of retatrutide?
Medvi provides compounded semaglutide and tirzepatide through licensed 503A pharmacies, a dissolvable GLP-1 tablet, and branded Wegovy and Zepbound under a separate membership. These are established GLP-1 and dual-agonist options with a documented clinical record, dispensed after licensed clinical review.
Does the genetic test predict retatrutide response?
No. The Precision Peptide Genetic Test does not predict response to retatrutide or any compound. It maps pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe your baseline metabolic biology — context that stays relevant across the incretin class regardless of which compound is used.
This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Medvi vs Direct Meds: Medication Options and Eligibility Compared
Medvi and Ozempic: Compounded Semaglutide vs the Brand